Showing results (211-220 of 389) with videos related to

Sort By:
Pageof 39
Cancer Science|July 3, 2019
Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysisTomonori Hirashima, Miyako Satouchi, Toyoaki Hida, et al.
Thoracic Cancer|April 23, 2025
Chest Tube Drainage, Bone Radiotherapy, and Brain Radiotherapy in Advanced Lung Cancer: A Retrospective Analysis of Associated Factors and SurvivalShoko Sonobe Shimamura, Takehito Shukuya, Kazuhisa Takahashi, et al.
Lung Cancer (Amsterdam, Netherlands)|October 23, 2019
Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving anti-PD-1 therapyYuki Ikematsu, Kentaro Tanaka, Toyoshi Yanagihara, et al.
Diagnostics (Basel, Switzerland)|November 18, 2020
Integrated Immunohistochemical Study on Small-Cell Carcinoma of the Lung Focusing on Transcription and Co-Transcription FactorsYounosuke Sato, Isamu Okamoto, Hiroki Kameyama, et al.
Lung Cancer (Amsterdam, Netherlands)|May 4, 2025
Epidemiology and clinical course of large cell neuroendocrine carcinoma of the lung: The Japanese lung cancer registry studyYukina Shirai, Takehito Shukuya, Tetsuhiko Asao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2015
Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung CancerKeiichi Ota, Koichi Azuma, Akihiko Kawahara, et al.
Oncogene|July 26, 2002
Elevated JNK activation contributes to the pathogenesis of human brain tumorsMarc A Antonyak, Lawrence C Kenyon, Andrew K Godwin, et al.
Japanese Journal of Clinical Oncology|December 4, 2018
Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subsetYuichiro Ohe, Fumio Imamura, Naoyuki Nogami, et al.
Scientific Reports|January 15, 2021
Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse eventsRyosuke Matsukane, Hiroyuki Watanabe, Haruna Minami, et al.
Thoracic Cancer|November 25, 2016
Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A)Minoru Fukuda, Midori Shimada, Takeshi Kitazaki, et al.
Pageof 39